



1 **Association between promoter IL-4 C 590-T polymorphism and asthma in**  
2 **Tunisian patients**

3  
4 **Mnasria Kaouther, MD<sup>1</sup>, Mzoughi Rania, MS<sup>1</sup>, Moatamri Zyed, PhD<sup>2</sup>, Oueslati Ridha,**  
5 **PhD<sup>1</sup>, and Ghazouani Ezzeddine, PhD<sup>3</sup>**

6 **(1) Laboratory of Microbiology - Immunology and Cancerogenesis. Life Science**  
7 **Department. Science Faculty of Bizerte. Jarzouna 7021 Bizerte Tunisia**

8 **(2) Pneumology Service. Military Hospital of Instruction of Tunisia. Mont Fleury-**  
9 **1008 Tunis. Tunisia**

10 **(3) Immunology Service. Military Hospital of Instruction of Tunisia. Mont Fleury-**  
11 **1008 Tunis. Tunisia**

12 **Corresponding author: Mnasria Kaouther**

13 **Email: [mnasriasmakouther@yahoo.fr](mailto:mnasriasmakouther@yahoo.fr)**

14

15

**Abstract**

16 Asthma is a common familial syndrome due to interacting genetic and environmental factors  
17 (1) (2). The aim of this study was to investigate the potential link between C590-T, the level  
18 of IL-4 and asthma prevalence in Tunisian patients (3) (4). A cohort of 50 subjects including  
19 30 patients and 20 controls was analyzed, IL-4 concentrations were determined by ELISA  
20 test and IL-4 C590-T was determined by PCR-RFLP (Polymerase Chain Reaction –  
21 Restriction Fragment Length Polymorphism) method using BsmF enzyme (5). Serum levels of  
22 IL-4 were increased for asthmatic patients exceeding threshold (2pg/ml) reaching  $2.665 \pm 0.52$   
23 for CT genotype and  $2.185 \pm 0.8$  for TT genotype compared to controls.

24 Our findings revealed that IL-4 C590-T SNP (Simple Nucleotide Polymorphism) showed a  
25 significant difference between asthmatic patients and controls, when comparing TT vs CC  
26 (OR 0, 10077. 95% CI: 0, 0285 – 0, 4068 P value  $48.10^{-5}$ ) and TT vs CT (OR 9, 2857. 95%  
27 CI: 2.4583 – 35.0753 P value  $48.10^{-5}$ ) genotypes.

28 We also demonstrated that patients with heterozygous CT (63,3%) and homozygous TT  
29 (20%) showed significantly higher serum levels of IL-4, while wild genotype CC showed  
30 lower levels.

31 T allele seems to be associated with asthma especially CT combination (6) (7). This allele  
32 dominating in special population compared to others at genetic levels could be used as an  
33 indicator of genetic biomarkers inducing either pathogenesis or protection from the disease  
34 (8).

35 **Key Words:** C590-T, SNP (Simple Nucleotide Polymorphism), IL-4, Asthma, Tunisian  
36 patients

37

## 38 **Introduction**

39 Research on asthma has a long tradition for  
40 decades, one of the most popular ideas in  
41 asthma literatures is the idea that asthma is  
42 simply due to environmental factors.  
43 Recent theoretical researches have  
44 revealed that asthma is a common airway  
45 inflammatory disease (9), its pathogenesis  
46 is complex it results from several  
47 interactions between genetic predisposition  
48 and environmental factors (10) (11). Some  
49 350 million people currently suffer from  
50 asthma; the asthma death rate is growing  
51 up reaching about 260.000 ill persons (12)  
52 (13).

53 To underline in depth asthma pathogenesis  
54 several studies axed on the identification of  
55 genes related to asthma (14). These  
56 approaches have been influential in the  
57 field because of specific molecular patterns  
58 that seem predicting asthma. Th2  
59 lymphocyte play an important role in air  
60 way inflammation(15), subsequently more  
61 trials have been conducted targeting

62 molecules related to Th2 cells such as IL-  
63 4, IL-13, IL-10 (16).

64 There are growing appeals for IL-4 effect  
65 in the field of asthma. IL-4 is a low  
66 molecular weight polypeptide of 129 AA.  
67 The protein is encoded by a gene on  
68 chromosome Chr 5q23- 31 (20). Il-4 plays  
69 a critical role in immune responses by  
70 acting as a growth factor for Th2 cells and  
71 inducing Ig class switching to IgE(18).

72 In the present study we analyzed genetic  
73 association, the relationship between IL-4  
74 single nucleotide polymorphism SNP  
75 located on the promoter region and asthma.  
76 Polymorphism genes play a crucial role in  
77 cytokine production (19). The present  
78 study is among the first investigations  
79 carried on Tunisian asthmatic patients  
80 dealing with genotyping IL-4.

## 81 **Material and methods**

82 A total of 50 patients (30 asthmatics and  
83 20 healthy patients) were recruited. Studies  
84 were approved by the Center Institutional

85 Review Board. All patients were from 96 common test tube the serum was extracted  
 86 asthma outpatient clinic of Pneumology 97 serving for ELISA test to detect IL-4 level.  
 87 department of Military Hospital of Tunisia. 98 After extraction from peripheral blood  
 88 A short questionnaire was designed to 99 leukocytes using a QIAmp min Kit  
 89 ascertain the participants, all patients and 100 (Qiagen Tnc), DNA amplification was  
 90 controls were aged 5 to 75 years, 12 males 101 carried out by polymerase chain reaction  
 91 and 18 females. 102 (PCR)-restriction fragment length  
 92 Each patient was drawn with 5ml venous 103 polymorphism (RFLP), genotyping one  
 93 blood; 3ml treated EDTA Anticoagulants 104 SNP C590-T in the promoter region of IL-  
 94 serving to DNA extraction and genotyping. 105 4. Table 1  
 95 The remaining 2ml was collected in a

**Table 1:** Primers of IL-4 C590T

PRIMER	SEQUENCE
FORWARD	5'-ACTAGGCCTCACCTGATACG-3'
REVERSE	5'-GTTGTAATGCAGTCCTCCTG-3'

} C-590-T

106 The PCR conditions are summarized below on Table 2 and 3.

**Table 2:** PCR mix reaction for genotyping of IL-4 gene position –590 (C>T).

Component	Volume (μl)
Each primer (T or C allele + reverse)	1.5
DNA template	2
dMix	15
Taq polymerase	1.5

**Table 3:** PCR conditions for genotyping of IL-4 gene position –590 (C>T).

Steps	Temperature (°C)	Time
Denature template	94	5min
Initial denaturation	94	45sec
Annealing	60	35 cycles 45sec
Extension	72	
Final extension	72	10min

107 A blank amplification was always run to 113 2μl of Tango Buffer for a final volume of  
 108 check for the presence of contamination. 114 15μl.  
 109 Primers and probes were obtained from  
 110 NCBI database. 115 Electrophoresis of 15μl digest product and  
 116 DNA markers of various molecular weight  
 111 15μl PCR products were digested for 1 to 117 were charged above an Agarose gel  
 112 16 hours at 37°C with 1 to 2μl of BsmFI 118 (3% agarose /1Xtbe gel).The  
 119 electrophoresis gel was performed using

120 BioRad Wide mini Sub cell at 75V for  
121 1hour. We visualized the reaction stained  
122 by 10 $\mu$ l BET.

123 The restriction digest was carried at 37°C  
124 rather than 65°C, optimal temperature for  
125 BsmFI activity on account of undesirable  
126 temperature for Taq DNA polymerase  
127 activity at 37°C. BsmFI activity upholds  
128 50% of its efficacy.

129 Elisa test Enzyme Linked Immuno Sorbent  
130 Assay was adopted to detect the IL-4 level,  
131 the reagent were purchase from Invitrogen  
132 ThermoFisher SCIENTIFIC IL-4 Human  
133 ELISA Kit.

134 Microplate reader was provided by  
135 Biometra.

### 136 **Statistical analysis**

137 The data were normalized using Statistical  
138 differences for patients and controls were  
139 tested for Hardy Weinberg equilibrium  
140 using  $\chi^2$  test. Statistical analysis were  
141 performed using (Epi info) (V.7) and graph


142 Prism (V.8.1) programs. To evaluate the  
143 difference of several biological settings  
144 between patients and controls we used  
145 ANOVA test. The significance level was  
146 set at 0, 05.

### 147 **Results**

148 The first set of questions aimed to analyze  
149 the effects of polymorphism on the  
150 incidence of asthma. A promoter  
151 polymorphism of IL-4 gene (C-590 T) was  
152 screened by PCR - RFLP in Tunisian  
153 patients (asthmatics and controls).  
154 Interestingly, the polymorphism was  
155 correlated with IL-4 serologic levels.

156 In summary, these results show that: at the  
157 end of cleavage by BsmFI of IL-4 gene  
158 (252 bp full length), PCR product display  
159 two fragments of 192 bp and 60 bp. Figure  
160 1 illustrates this with examples of an  
161 homozygous for the wild type allele in lane  
162 2, an heterozygous in lane 1 and 3, and a  
163 homozygote for the -590 C->T allele in  
164 lane 4. Under these electrophoresis

165 conditions the 60 bp cleavage product is 168 CT, and TT) by using the specific C,  
166 not visible. The polymorphism of IL4 169 specific T, and reverse primers (Figure 1).  
167 -590 (C>T) showed three genotypes (CC,



170

171 **Figure 1:** *BsmFI* restriction endonuclease digestion of PCR products amplified of IL-4 gene  
172 sequence; 1 and 3= Heterozygous for the -590C/T allele (CT), 2= Homozygous for the wild  
173 type allele (CC) and 4= Homozygous for mutant -590C/T (TT).


174 These results suggest that there is an 178 590T polymorphism between asthmatics  
175 association between polymorphism and 179 patients and controls (83, 3% vs. 35%)  
176 asthma. Significant differences were found 180 respectively, Table4 shows an overview  
177 in the genotype distribution of SNP C- 181 of statistical analysis.

**Table 4:** Frequency distribution of IL4 -590 (C>T) genotypes in asthma patients and controls.

Gene	Genotype	Asthma patients number (%)	Controls number (%)	OR (95% CI)	P-value
IL-4 -590 (C>T)	CC	5 (16.6)	13 (65)	0.1077 (IC = 0.0285-0.4068)	$48 \times 10^{-5}$
	CT	19 (63.3)	4(20)	9.2857 (IC = 2.4583-35.0753)	$48 \times 10^{-5}$
	TT	6 (20)	3(15)	9.7879 (IC = 2.3317-41.0872)	$2.05 \times 10^{-3}$

(OR = odds ratio, CI = confidence intervals).

182 The most striking result to emerge from the 184 related to asthma in Tunisian patients with  
183 data is that C590T polymorphism was 185 a high significance  $p < 0,005$ .Figure 2



186

187 **Figure 2:** Phenotypic study of control and patients groups. The frequencies show that the C  
188 allele is more frequent in controls compared to the T allele; however in asthmatic patients T  
189 allele is more expressed. CT combination in the patient group is over-represented compared

7

190 to other genotypes (63%). The distribution of TT genotype was an approximate proportion  
 191 between patients and controls; 15% in controls VS 20% for patients.

192 CT genotype was associated with a 202 with risk of asthma for both of CT and TT.  
 193 potential link with asthma (OR=9.2857; 203 We also detected an increased  
 194 95%IC: 2.4583-35.0753  $p < 0,005$ ). We 204 susceptibility of asthma for CT  
 195 found that there is no significant 205 combination.

196 association between CC genotype the wild 206 If we now turn to serologic analysis we  
 197 genotype, however T allele conveys a 207 measured IL-4 levels, we detected  
 198 significantly increased risk of asthma 208 remarkably increased levels in asthmatic  
 199 which is consistent with other studies. 209 patients compared to controls.

200 Taken together the two mutant genotypes 210 As shown in table 5:  
 201 we observed a trend towards association


211 **Table 5:** Serum IL-4 concentration (pg/ml) in control and patient's groups.

Interleukine 4 [pg/ml]	controls n=20	Patients n=30
		0.978 ± 0.89
<b>p-value = 0.013</b>		

212 The concentration of IL-4 was elevated in patient's group at an average of 1.663±1.02 pg/ml.  
 213 While the control group it was normal for an average of 0.978 ± 0.89 pg/ml.

214 Serum concentration of IL-4 in asthmatic 217 under the thresholds 0,4pg/ml. Figure3  
 215 patients exceeded the threshold reaching 218 below provides the results obtained from  
 216 2,66pg/ml however in controls levels were 219 the preliminary analysis.





220

221 **Figure 3:** *IL-4 serum concentration (pg/ml) in control group and patients.*

222 The overall outcome of the survey is that  
 223 T allele promotes the development of  
 224 asthma. IL-4 is significantly over  
 225 expressed within asthmatic patients it  
 226 means that the immune dysfunction  
 227 contributes to the development and  
 228 progression of asthma.

229 **Discussion**

230 New trends in human genetics have  
 231 demonstrated that gene alterations play a  
 232 crucial role in asthmatic diseases (20)  
 233 Several reports have also shown that IL-4,  
 234 which is a Th2 cytokine, is a part of the  
 235 complex net work of allergic  
 236 inflammation, An initial objective of the  
 237 study was aimed on the fact that

238 substitution of C590T in IL-4 gene which  
 239 may affect asthma prevalence (9).

240 This study set out with the aim of assessing  
 241 the importance of IL-4 in asthma. In  
 242 accordance with previous studies the  
 243 current work have demonstrated that IL-4  
 244 polymorphism effects in a population help  
 245 to bring insight into pathogenesis of  
 246 asthma (22) (23). We have determined a  
 247 single nucleotide polymorphism SNP (C-  
 248 590 T) of IL-4 effects in Tunisian patients.

249 The most obvious finding to emerge from  
 250 the analysis is that there were differences  
 251 in genotype frequencies in the cohort study  
 252 of asthmatics and controls. An association  
 253 between C-590 T IL-4 polymorphism and  
 254 asthma has been found especially for

255 mutated genotypes CT and TT, although  
256 this association is controversial (24). As  
257 shown in table 4 we have found that T  
258 allele is more expressed in asthmatic  
259 patients(25)(26).

260 The mutant TT presented higher frequency  
261 than the wild one CC and CT mutant  
262 showed the highest linkage with asthma  
263 incidence, the association of C and T allele  
264 seems to be the most implicated in the  
265 disease prevalence. The inconsistency  
266 between our findings and those of several  
267 previous studies may be at least partly  
268 explained by differences in the genetic  
269 backgrounds of the populations examined,  
270 definitions of asthma, and statistical  
271 power.(27)(28).

272 Also an increasing in IL-4 secretion has  
273 been reported in relation with T allele (29)  
274 (30), IL-4 increases throughout Th2  
275 differentiation inducing inflammation and  
276 may be a crucial factor promoting asthma  
277 (31) (32).

## 300 **References**

## 278 **In conclusion**

279 This paper has argued that C-590T  
280 polymorphism in IL-4 gene promoter has  
281 an influence on asthma. It has also found  
282 that generally C-590 T polymorphism was  
283 correlated to IL-4 high serum levels.

284 This finding is described for the first time  
285 for Tunisian patients, Asthma risk in  
286 Tunisian patients is tightly linked to T  
287 allele CT and TT genotypes frequencies  
288 were higher than in controls. And CT  
289 combination plays a crucial role in the  
290 development of the disease. This could be  
291 an important biomarker predicting asthma.  
292 Since our sample size was relatively small  
293 and only one SNP of IL-4 were genotyped,  
294 association or linkage study in larger  
295 sample size and multiple loci are needed to  
296 clarify the inheritance role of IL-4 in the  
297 development of asthma. Further studies,  
298 which take these variables into account,  
299 will need to be undertaken.

- 301 1. Mukherjee AB and Zhang 345  
 302 Z.2011.Allergic asthma: influence 346  
 303 of genetic and environmental 347  
 304 factors. J of Biol Chem 286:32883– 348  
 305 32889. 349  
 306 2. [Joobeur S](#), [Cheikh Mhamed S](#), 351  
 307 [Ben Saad A](#), [Mribah H](#), [Dekhil A](#), 352  
 308 [Rouatbi N](#), [El Kamel A](#).2015. 353  
 309 Allergic Asthma in central Tunisia. 354  
 310 Pan Afr Med J 20:133. 355  
 311 3. Berenguer AG, Camara RA, Brehm 356  
 312 AD, [Oliveira S](#), and [Fernandes AT](#). 357  
 313 2012. Distribution of 358  
 314 polymorphisms IL4-590 C/T and 359  
 315 IL4 RP2 in the human populations 360  
 316 of Madeira, Azores, Portugal, Cape 361  
 317 Verde and Guinea-Bissau. Int J 362  
 318 Mol Epidemiol Genet.3:179- 262. 363  
 319 4. De Guia RM, Ramos JD.2010. The 364  
 320 -590C/TIL4 single-nucleotide 365  
 321 polymorphism as a genetic factor of 366  
 322 atopic allergy.Int J Mol Epidemiol 367  
 323 Genet. 1 (1):67-73. 368  
 324 5. [Agache I](#), [Bild M](#), [Braunstaal](#) 369  
 325 [GJ](#), [Delgado L](#), [Demoly](#) 370  
 326 [P](#), [Eigenmann P](#), [Gevaert P](#), [Gomes](#) 371  
 327 [E](#), [Hellings P](#), [Horak F](#) et al. 372  
 328 2015.In vivo diagnosis of allergic 373  
 329 diseases allergen provocation tests. 374  
 330 Allergy 70:355-365. 375  
 331 6. Dixit P, Awasthi S and Agarwal 376  
 332 S.2015. Association of interleukin 377  
 333 genes polymorphism with asthma 378  
 334 susceptibility in Indian children: a 379  
 335 case-control study. Annals of 380  
 336 Human Biology 42:552– 559. 381  
 337 7. Bai S, Hua L, Wang X Liu Q , Bao 382  
 338 Y et al. 2018. Association of a 4- 383  
 339 Locus Gene Model Including IL13, 384  
 340 IL4, FCER1B, and ADRB2 With 385  
 341 the Asthma Predictive Index and 386  
 342 Atopy in Chinese Han Children. J 387  
 343 Investig Allergol Clin Immunol. 388  
 344 28(3): 407-413. 389  
 390  
 391 8. [Lawson JA](#), [Chu LM](#), [Rennie DC](#),  
 Hagel L, Krunanayake PC, Pahwa  
 P, Dosman JA et al.2017.  
 Prevalence, risk factors, and  
 clinical outcomes of atopic and  
 nonatopic asthma among rural  
 children. Ann  
 Allergy Asthma Immunol 118: 304  
 – 310.  
 9. Kubo M.2017. Innate and adaptive  
 type 2 immunity in  
 lung allergic inflammation.  
 Immunol Rev 1:162- 172.  
 10. Samitas K, Carter A, Kariyawasam  
 HH, [Xanthou G](#).2018. Upper and  
 lower airway  
 remodelling mechanisms in asthma,  
 allergic rhinitis and chronic  
 rhinosinusitis: The one airway  
 concept revisited. Allergy 73:993-  
 1002.  
 11. Koppelman GH.2006. Gene by  
 environment interaction in asthma.  
 Curr. Allergy Asthma Rep 6:103–  
 111.  
 12. [Kondo M](#) and [Tamaoki J](#).2018.  
 Therapeutic approaches  
 of asthma and COPD overlap.  
 Allergol Int 67:187- 190.  
 13. Compalati E, Ridolo E, Passalacqua  
 G, Braido F, Villa E, Canonica  
 GW.2010. The link between  
 allergic rhinitis and asthma: the  
 united airways disease. Expert Rev  
 Clin Immunol 6 (3):413-23.  
 14. Xingnan Li, Gregory AH, Moore  
 WC. [Hastie AT](#), [Ampleford AJ](#),  
[Milosevic J](#) et al. 2016. Expression  
 of asthma susceptibility genes in  
 bronchial epithelial cells and  
 bronchial alveolar lavage in the  
 Severe Asthma Research Program  
 (SARP) cohort.J Asthma 53(8):  
 775–782.  
 15. Scanlon ST and McKenzie AN.  
 2015. The messenger between  
 worlds: the regulation of innate and

- 392 adaptive type-2 immunity by innate 438  
 393 lymphoid cells. Clin Exp Allergy 439  
 394 45:9- 20. 440
- 395 16. Parulekar AD, Kao CC, Diamant Z, 441  
 396 [Hanania NA](#). 2018. Targeting the 442  
 397 interleukin-4 and interleukin-13 443  
 398 pathways in severe asthma: current 444  
 399 knowledge and future needs. Curr 445  
 400 Opin Pulm Med24:50- 55. 446
- 401 17. Kim BS, Park SM, Uhm TG, [Kang](#) 448  
 402 [JH](#), [Park JS](#), [Jang AS](#) et al. 2010. 449  
 403 Effect of single nucleotide 450  
 404 polymorphisms within the 451  
 405 interleukin-4 promoter on aspirin 452  
 406 intolerance in asthmatics and 453  
 407 interleukin-4 promoter activity. 454  
 408 Pharmacogenet Genomics 20:748- 455  
 409 758. 456
- 410 18. Kabesch M, Tzotcheva I, Carr D, 457  
 411 [Höfler C](#), [Weiland SK](#), [Fritsch C](#) 458  
 412 et al.2003. A complete screening of 459  
 413 the IL4 gene: novel polymorphisms 460  
 414 and their association with asthma 461  
 415 and IgE in childhood. J Allergy 462  
 416 Clin Immunol 112:893-901. 463
- 417 19. Micheal S, Minhas K, Ishaque M, 464  
 418 [Ahmed F](#), [Ahmed A](#).2013. *IL-4* 465  
 419 Gene Polymorphisms and Their 466  
 420 Association With Atopic Asthma 467  
 421 and Allergic Rhinitis in Pakistani 468  
 422 Patients. J Investig Allergol Clin 469  
 423 Immunol 23(2): 107-111. 470
- 424 20. Akkad D, Arning L, Ibrahim S and 471  
 425 [Epplen JT](#). 2007. Sex specifically 472  
 426 associated promoter polymorphism 473  
 427 in multiple sclerosis affects 474  
 428 interleukin 4 expression levels. 475  
 429 Genes Immun 8:703-706. 476
- 430 21. Chai R, Liu B and Qi F. 2017. The 477  
 431 significance of the levels of IL-4, 478  
 432 IL-31 and TLSP in patients 479  
 433 with asthma and/or rhinitis. 480  
 434 Immunotherapy 9:331- 337. 481
- 435 22. Kelly-Welch AE, Hanson EM, 482  
 436 Boothby MR, [Keegan AD](#). 2003. 483  
 437 Interleukin-4 and interleukin-13 484  
 signaling connections maps. 485  
 Science 300:1527- 1528. 486
23. Hussein IA and Jaber SH.2017. 487  
 Genotyping of *IL-4* -590 (C>T) 488  
 Gene in Iraqi Asthma Patients. Dis 489  
 Markers 10: ID 5806236, 5 pages. 490
24. Nie W, Zhu Z, Pan X, [Xiu Q](#). 2013. 491  
 The interleukin-4 – 589C/T 492  
 polymorphism and the risk of 493  
 asthma: A meta-analysis including 494  
 7345 cases and 7819 controls. Gene 495  
 520:22– 29. 496
25. Anovazzi G, Medeiros MC, Pigossi 497  
 SC, [Finoti LS](#), [Souza Moreira](#) 498  
 TM, [Mayer MPA](#) et al. 2017. 499  
 Functionality and opposite roles of 500  
 two interleukin 4 haplotypes in 501  
 immune cells. Genes and Immunity 502  
 18: 33–41. 503
26. Xue-Xi Yang, Fen-Xia Li, Ying- 504  
 Shong Wu, Dong Wu, Jia-Yu Tan, 505  
 Ming Li. 2011. Association of 506  
 TGF-β, IL-4 and IL-13 gene 507  
 polymorphisms with asthma in a 508  
 Chinese population. Asian Pac J 509  
 Allergy Immunol 29:273-7. 510
27. Patella V, Florio G, Magliacane D, 511  
[Giuliano A](#), [Crivellaro MA](#), [Di](#) 512  
[Bartolomeo D](#) et al. 2018.Urban air 513  
 pollution and climate change: "The 514  
 Decalogue: Allergy Safe Tree" 515  
 for allergic and respiratory diseases 516  
 care. Clin Mol Allergy 3:16- 20. 517
28. Akdis CA, Akdis M. 2011. 518  
 Mechanisms of allergen-specific 519  
 immunotherapy. J. Allergy Clin. 520  
 Immunol 127:18- 27. 521
29. Haahtela T, Selroos O.2018. A 522  
 population management model of 523  
 asthma and allergy: Case Finland. 524  
 Personalizing asthma management 525  
 for the clinician, 1st ed. St.Louis, 526  
 Missouri: Elsevier Publishing. 1– 527  
 10. 528

- 482 30. Kyewski B, Klein LA.2018. Central  
483 role for central tolerance. Annu  
484 Rev Immunol 24:571-606.
- 485 31. Larsen JN, Broge L, Jacobi H.  
486 2016. Allergy immunotherapy: the  
487 future of allergy treatment. Drug  
488 Discov Today 21:26- 37.
- 489 32. Lougheed MD, Lemiere C,  
490 Ducharme FM, Licskai C, Dell  
491 SD, Rowe BH et al. 2012.  
492 Canadian thoracic society 2012  
493 guideline update: diagnosis and  
494 management of asthma in  
495 preschoolers, children and  
496 adults. Can Respir J 19:127– 164.

